180 likes | 283 Views
Measles Initiative Management and Financing September 13, 2011. Overview. MI management and finance mechanism strengths and challenges Financial update. MI Process. Management. Disbursement. Management - Strengths. Country driven No secretariat Flexible Transparent
E N D
Measles Initiative Management and Financing September 13, 2011
Overview • MI management and finance mechanism • strengths and challenges • Financial update
MI Process Management Disbursement
Management - Strengths • Country driven • No secretariat • Flexible • Transparent • Defined roles and responsibilities: with shared responsibility and credit • Well coordinated: avoids programme fragmentation • Clearly defined monitoring and evaluation indicators and process • Accountable: accurate & detailed reporting of results & resources on annual basis
Management Balance needs of each partner agency with needs of the MI MI communication/advocacy support hired MI branded communication tools MI.org, Facebook, Twitter, Storify, etc. Challenge Tactic
Management Raise awareness of partnership and goals Advocacy survey Inform direction of MI advocacy team MI advocacy team (MIAT) Finalizing TORs, structure and management, short-term workplan Challenge Tactic
Financial Mechanism ARC CDC UNF (matching funds) Other Donors “The Measles Fund” (Donor Partners) UNFIP Operational Costs, Technical Assistance, and Lab/Surveillance WHO/HQ UNICEF/NY UNICEF/Supply Country Plans Vaccine/ Syringes WHO/Country UNICEF/Country (UN Partners) ICC MOH, Red Cross/Crescent Societies, Lions, LDS and other NGOs Country Plans (In-Country Partners) Note: Funds are released when ICC-approved country plans are approved by partners.
Financial Mechanism - Strengths • Flexible • Rapid and full disbursement of funds • Able to balance WHO and UNICEF funding needs in different settings • Low overhead costs • Low transaction costs for donors, partners and countries (one pooled donor fund, one proposal, one report) • Streamlined: joint resource mobilization
Decline in funds available Additional resource mobilization support TORS developed, interviews underway New partners Measles mortality reduction investment case (Dec. 2011) Eradication investment case (Apr. 2012) High net worth individuals investment case (near final) Financial Mechanism Challenge Tactic Measles Initiative Annual Donations, 2001-2011* *Excluding country contributions
Financial Mechanism Large outbreaks that require emergency ORI $30m in 2010 and in 2011 Sufficient funds for high quality preventative campaigns Ongoing discussions regarding outbreak response fund Coordination with other humanitarian agencies Challenge Tactic Measles Case Distribution by Month, Sub-Saharan Africa 2006-2010
Financial Mechanism Non-binding agreement with countries to finance 50% of SIA costs On-going discussions with GAVI and other partners to explore common standards for implementing country co-financing MI advocacy team to focus on raising political and financial commitment from implementing countries Challenge Tactic
Historic Measles Initiative Support • Technical • Vaccination and surveillance strategies • Program planning, implementation, M and E • Financial • Bundled vaccine • SIA operational costs • 100% catch-up campaigns • 50% for follow-up campaigns • Lab and surveillance • Technical assistance • Advocacy and communication
Additional Cost Elements to Achieve Goals • Research • Outbreak response • Routine • Scale up of MCV1 • MCV2 introduction • Rubella • Catch-up campaigns • Introduction into routine
Annual Donations 2001-2011 and Financial Resource Requirements, Projections, Funding Gap 2012 Funding Gap 2012: $43.4 million * Excluding country contributions
External Contributions, Projected Contributions and Funding Gap for 2001-2012 Total: $987 million (excluding country contributions for follow-up SIAs, & intro. of MCV2) 2012 funding gap US$43.4 m *includes ARC and partners: ARC chapter contributions, Anne Ray Charitable Trust, BD, Herman and Katherine Peters Foundation, and others ** includes UNF and partners
Next Steps • Financial resource requirements, 2011-2015 • Measles eradication investment case • global burden of disease • expected benefits, risks, and costs of the eradication and comparator options (i.e., control) • social, political, and economic challenges • ethical considerations • operational and other research needs • different financial instruments and funding mechanisms • options for management and governance